主要目的：评价在含铋剂四联疗法中联合 X842 胶囊对比联合艾司奥美拉唑镁肠溶片（耐信®）对所有 Hp阳性（+）受试者进行 Hp 根除治疗的疗效，以验证 X842 胶囊辅助根除 Hp 的疗效非劣效于艾司奥美拉唑镁肠溶片；次要目的：评价在含铋剂四联疗法中联合 X842 胶囊对比联合艾司奥美拉唑镁肠溶片（耐信®）对克拉霉素耐药的 Hp+受试者进行 Hp 根除治疗的疗效；评价在含铋剂四联疗法中联合 X842 胶囊对比联合艾司奥美拉唑镁肠溶片（耐信®）对阿莫西林耐药的 Hp+受试者进行 Hp 根除治疗的疗效；评价含铋剂四联疗法中联合 X842 胶囊对所有 Hp+受试者进行 Hp 根除治疗的安全性。

开始日期2026-03-11

申办/合作机构

上海生诺医药科技有限公司

[+1]

NCT07313774

/ Withdrawn临床3期

A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Linaprazan Glurate Compared to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D

The goal of this clinical trial is to investigate how well linaprazan glurate can maintain healed erosive esophagitis (EE) caused by GERD in participants who have participated in a prior healing trial, compared to lansoprazole (an approved treatment for GERD). Researchers will also examine:
* the effect of linaprazan glurate on heartburn symptoms compared to lansoprazole.
* whether linaprazan glurate treatment is safe and tolerable, based on symptoms and procedures such as blood and urine tests, endoscopy, and electrocardiograms (measure the heart's electrical activity). Endoscopy means that the doctor will insert a thin, flexible tube with a camera down the throat to look at each participant's esophagus area and collect small tissue samples (called biopsies).
* the side effects that may happen during treatment with linaprazan glurate.
Participants must be between 18 to 80 years old and have participated in a prior healing trial with healed EE (due to GERD) confirmed by an endoscopy either from the prior healing trial or from the initial period of this trial. Participants cannot participate if they are not healed, had to stop trial treatment because of a side effect in a prior healing trial, or if they have a condition that could make it unsafe.
The study is a randomized, double-blind, active comparator-controlled clinical trial lasting for almost 14 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups:
* Linaprazan glurate - High dose
* Linaparazan glurate - Low dose, and
* Lansoprazole - marketed approved dose Everyone will take a total of 2 tablets and 1 capsule orally every day for up to 52 weeks. The tablets and capsule will be separated into a morning dose and an evening dose. Some tablets or capsules will be placebos (look like medicine but contain no active drug).
Participants will complete several questionnaires on an electronic device during treatment. An endoscopy will be performed after 24 weeks of treatment to determine if healing has been maintained. If healing has been maintained, the participant will continue taking trial treatment and another endoscopy will be performed at 52 weeks. If healing has not been maintained at 24 weeks or if the participant has reached 52 weeks, the participant will stop taking trial treatment and return for a follow up visit.

开始日期2026-03-01

申办/合作机构

Cinclus Pharma Holding AB

CTR20254718

/ Recruiting临床3期

多中心、随机、双盲双模拟、阳性药平行对照的Ⅲ期临床研究评价X842胶囊用于十二指肠溃疡患者的有效性和安全性

主要目的：评价X842胶囊每日1次50mg连续给药4到6周对十二指肠溃疡的内镜下溃疡愈合的有效性，以验证X842胶囊在6周内的内镜下溃疡愈合受试者比例非劣效于兰索拉唑肠溶胶囊；次要目的：与兰索拉唑肠溶胶囊相比，评价X842胶囊改善十二指肠溃疡受试者的临床症状（上腹疼痛、胃烧灼感、反酸、恶心、呕吐、嗳气和腹胀）的有效性；与兰索拉唑肠溶胶囊相比，评价X842胶囊治疗十二指肠溃疡的安全性；观察X842胶囊用于十二指肠溃疡患者后血清胃泌素的治疗前后变化情况。

开始日期2025-12-17

申办/合作机构

上海生诺医药科技有限公司

[+1]

100 项与戊二酸利那拉生酯相关的临床结果

登录后查看更多信息

100 项与戊二酸利那拉生酯相关的转化医学

登录后查看更多信息

100 项与戊二酸利那拉生酯相关的专利（医药）

登录后查看更多信息

项与戊二酸利那拉生酯相关的文献（医药）

2025-05-01·ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Trial: Dose‐Finding Study of Linaprazan Glurate, A Novel Potassium‐Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis

Article

作者: Michael Vaezi ; Kajsa Larsson ; Elham Yektaei ; Peter Unge ; Maria Rosenholm ; Andras Rosztóczy ; Prateek Sharma ; David Armstrong ; Ivan Popadiyn ; Kjell Andersson

ABSTRACT:

Background:

Linaprazan glurate, a potassium‐competitive acid blocker, is in development for the treatment of erosive oesophagitis and other acid‐related diseases.

Aim:

To evaluate the 4‐week healing rate and safety of four linaprazan glurate dosing regimens in patients with erosive oesophagitis.

Methods:

This double‐blind, dose‐finding study compared linaprazan glurate to lansoprazole. We included patients with endoscopically confirmed erosive oesophagitis (validated by a central review board) if they had Los Angeles (LA) grade C/D or LA grade A/B with partial response to at least 8 weeks of proton pump inhibitor therapy. Patients were randomised to 4 weeks of linaprazan glurate (25, 50, 75 or 100 mg twice daily) or lansoprazole (30 mg once daily), followed by 4 weeks of open‐label lansoprazole.

Results:

Of 248 patients randomised, central review confirmed erosive oesophagitis in 182 at screening endoscopy. Across all doses, linaprazan glurate achieved a 4‐week healing rate of 71.1% in intention‐to‐treat (ITT) analysis and 80.9% in per protocol (PP) analysis. In comparison, lansoprazole achieved healing rates of 60.6% (ITT) and 59.1% (PPS). The best performing linaprazan glurate dosing group outperformed lansoprazole by 28% in patients with LA grade A/B with partial PPI response and by more than 50% in patients with LA grade C/D.

Conclusions:

Linaprazan glurate demonstrated high 4‐week healing rates compared to lansoprazole, with a good safety profile, supporting its further development.

Trial Registration:

ClinicalTrials.gov: NCT05055128; EudraCT: 2020‐003319‐91

2024-11-01·Current gastroenterology reports

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Review

作者: Scarpignato, Carmelo ; Hunt, Richard H

Abstract:

Purpose of the Review:

Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice.

Recent Findings:

Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs.

Summary:

Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that—in the above two clinical indications—P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

2024-05-01·Journal of pharmaceutical and biomedical analysis

Absorption, distribution, metabolism and excretion of linaprazan glurate in rats

Article

作者: Jin Xiu ; Ying Yang ; Donghui Liu ; Ming Lu ; Chen Yang ; Xingxing Diao ; Xinyue Zhang ; Yali Yuan ; Yuandong Zheng ; Pingsheng Hu

Linaprazan (AZD0865, TX07) is one of potassium-competitive acid blockers. However, linaprazan is rapidly excreted from the body, shortening its acid inhibition property. Linaprazan glurate (X842) is a prodrug of linaprazan with a prolonged inhibitory effect on gastric acid secretion. Linaprazan glurate has entered clinical trials, but few studies have reported its metabolism in non-clinical and clinical settings. In this study, we studied the pharmacokinetics, tissue distribution, mass balance, and metabolism of linaprazan glurate in rats after a single oral dose of 2.4 mg/kg (100 µCi/kg) [¹⁴C]linaprazan glurate. The results demonstrated that linaprazan glurate was mainly excreted via feces in rats with 70.48% of the dose over 168 h. The plasma AUC₀_-_∞ of linaprazan glurate in female rats was 2 times higher than that in male rats. Drug-related substances were mainly concentrated in the stomach, eyes, liver, small intestine, and large intestine after administration. In blood, drug-related substances were mostly distributed into plasma instead of hemocytes. In total, 13 metabolites were detected in rat plasma, urine, feces, and bile. M150 (2,6-dimethylbenzoic acid) was the predominant metabolite in plasma, accounting for 80.65% and 67.65% of AUC_0-24_h in male and female rats, respectively. Based on the structures, linaprazan glurate was mainly hydrolyzed into linaprazan, followed by a series of oxidation, dehydrogenation, and glucuronidation in rats. Besides, CES2 is the main metabolic enzyme involved in the hydrolysis of linaprazan glurate to linaprazan.

141

项与戊二酸利那拉生酯相关的新闻（医药）

2026-08-28

·今日头条

找准特色赛道打造创新药竞争力 | 访贵州医科大学副校长潘卫东

近年来，贵州立足得天独厚的中药材与民族医药资源优势，积极探索“资源产业化、产业创新化”发展路径，持续推动传统医药资源优势向现代创新药产业优势、区域竞争胜势转变。在全国创新药产业竞争日趋激烈的当下，贵州如何立足自身禀赋、补齐发展短板，精准布局特色细分赛道、构筑差异化竞争力？贵州医科大学副校长潘卫东近日在接受天眼新闻记者访谈时表示，贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦特色细分领域，打造专属竞争优势。制图鲍贝贝天眼新闻记者：贵州作为全国四大中药材主产区之一，中药材资源与种植规模居全国前三。这种资源禀赋为贵州发展创新药提供了怎样的“先天优势”？潘卫东：中药材资源与种植规模位居全国前三的禀赋，为贵州发展创新药提供了从“标准化原料供给”到“特色民族药研发”的系统性先天优势，为贵州从中药资源大省迈向产业强省奠定了核心基础。贵州发展创新药的“先天优势”，并非只是“家里有矿”，而是已形成一个以特有物种资源为“根”、以民族医药宝库为“魂”、以科研转化平台为“脑”、以政策产业生态为“体”的完整系统。其核心优势在于，为创新药研发提供了从独特的先导化合物来源，到经过初步验证的民族医药经验，再到全链条产业化的闭环支持。天眼新闻记者：在您看来，当前贵州创新药产业的整体“家底”如何？对比国内创新药第一梯队省份，贵州发展创新药最突出的短板和痛点集中在哪些方面？潘卫东：贵州创新药产业的整体“家底”，可以概括为：一个厚积薄发、正处于从“资源大省”向“产业强省”跨越关键期的产业集群。近几年呈现出从“量变”走向“质变”的鲜明特征。一方面是产业规模与集群效应初步显现。贵州中药材、苗药等民族药资源禀赋突出，是产业发展独特根基，科研与产业开发均立足该资源优势。贵阳（乌当、修文）健康医药产业园产业集聚效应显著，为中药民族药产业转型发展夯实了基础。贵阳市健康医药（化学药）产业园另一方面是实现多项从0到1的突破与全链条升级。一是本土首个1.1类化学创新药——贵州生诺生物研发的戊二酸利那拉生酯胶囊获批上市并纳入医保；二是苗药成果转化取得重大进展，苗药验方“脊蛇祛湿胶囊”以1500万元完成转化，创下省内中医药单品种转化金额新高，打通民族验方向新药转化的关键通道；三是贵州金玖生物两款特医食品获批，补齐特医食品产业空白，开辟全新赛道。然而，对比国内创新药一线省份，贵州医药产业长板突出、短板集中，资源优势难以转化为竞争优势。其痛点体现在创新质效低、产业结构失衡，高端研发人才短缺、产学研转化不畅，科创研发耐心资本不足、融资难，同时产业龙头缺失、配套不完善、标准化与数字化水平偏低，产业综合竞争力偏弱。天眼新闻记者：立足贵州实际，未来我省创新药应当优先主攻哪些细分赛道，走出差异化发展路径？潘卫东：贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦三大特色细分领域，打造专属竞争优势。 7月29日，民族药AI大模型在贵州发布第一，深耕中药民族药创新现代化赛道，筑牢核心护城河。依托全省唯一的中药功效成分发掘与利用国家级重点实验室，做强特色优势产业。一方面推进肺力咳合剂、仙灵骨葆胶囊等爆款单品二次开发与技术升级；另一方面借鉴苗药验方高价值转化经验，推动医院制剂、民间民族验方新药转化，同时加快苗医特色诊疗技术标准化、产品化、市场化。第二，攻坚特色化学原料药与制剂赛道，补齐产业链短板。以息烽全省唯一化学原料药产业园为核心载体，依托现有入驻企业产业基础，布局高端医药中间体、特色原料药及仿制药制剂。不断对标东部全链条创新，重点承接东部产业转移，完善配套产能，同时为省内民族药剂型改良提供技术支撑，联动瓮安生物医药产业园拓展产业空间。第三，前瞻布局前沿生物药赛道，实现单点精准突破。立足省内科研优势，避开疫苗、抗体药等红海领域，聚焦细胞治疗、体外诊断设备等细分领域。重点扶持贵州医科大学CAR-NK细胞治疗项目，依托乌当国药西部医疗产业园等平台，打造低成本、可量产、无需配型的特色细胞治疗产品，以“小而精”的前沿布局抢占未来产业赛道。天眼新闻记者鲍贝贝编辑郭立二审管云三审岳振

2026-08-28

·当代先锋网

找准特色赛道打造创新药竞争力 | 访贵州医科大学副校长潘卫东

近年来，贵州立足得天独厚的中药材与民族医药资源优势，积极探索“资源产业化、产业创新化”发展路径，持续推动传统医药资源优势向现代创新药产业优势、区域竞争胜势转变。在全国创新药产业竞争日趋激烈的当下，贵州如何立足自身禀赋、补齐发展短板，精准布局特色细分赛道、构筑差异化竞争力？　　贵州医科大学副校长潘卫东近日在接受天眼新闻记者访谈时表示，贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦特色细分领域，打造专属竞争优势。制图鲍贝贝　　天眼新闻记者：贵州作为全国四大中药材主产区之一，中药材资源与种植规模居全国前三。这种资源禀赋为贵州发展创新药提供了怎样的“先天优势”？　　潘卫东：中药材资源与种植规模位居全国前三的禀赋，为贵州发展创新药提供了从“标准化原料供给”到“特色民族药研发”的系统性先天优势，为贵州从中药资源大省迈向产业强省奠定了核心基础。　　贵州发展创新药的“先天优势”，并非只是“家里有矿”，而是已形成一个以特有物种资源为“根”、以民族医药宝库为“魂”、以科研转化平台为“脑”、以政策产业生态为“体”的完整系统。其核心优势在于，为创新药研发提供了从独特的先导化合物来源，到经过初步验证的民族医药经验，再到全链条产业化的闭环支持。　　天眼新闻记者：在您看来，当前贵州创新药产业的整体“家底”如何？对比国内创新药第一梯队省份，贵州发展创新药最突出的短板和痛点集中在哪些方面？　　潘卫东：贵州创新药产业的整体“家底”，可以概括为：一个厚积薄发、正处于从“资源大省”向“产业强省”跨越关键期的产业集群。近几年呈现出从“量变”走向“质变”的鲜明特征。　　一方面是产业规模与集群效应初步显现。贵州中药材、苗药等民族药资源禀赋突出，是产业发展独特根基，科研与产业开发均立足该资源优势。贵阳（乌当、修文）健康医药产业园产业集聚效应显著，为中药民族药产业转型发展夯实了基础。贵阳市健康医药（化学药）产业园　　另一方面是实现多项从0到1的突破与全链条升级。一是本土首个1.1类化学创新药——贵州生诺生物研发的戊二酸利那拉生酯胶囊获批上市并纳入医保；二是苗药成果转化取得重大进展，苗药验方“脊蛇祛湿胶囊”以1500万元完成转化，创下省内中医药单品种转化金额新高，打通民族验方向新药转化的关键通道；三是贵州金玖生物两款特医食品获批，补齐特医食品产业空白，开辟全新赛道。　　然而，对比国内创新药一线省份，贵州医药产业长板突出、短板集中，资源优势难以转化为竞争优势。其痛点体现在创新质效低、产业结构失衡，高端研发人才短缺、产学研转化不畅，科创研发耐心资本不足、融资难，同时产业龙头缺失、配套不完善、标准化与数字化水平偏低，产业综合竞争力偏弱。　　天眼新闻记者：立足贵州实际，未来我省创新药应当优先主攻哪些细分赛道，走出差异化发展路径？　　潘卫东：贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦三大特色细分领域，打造专属竞争优势。7月29日，民族药AI大模型在贵州发布　　第一，深耕中药民族药创新现代化赛道，筑牢核心护城河。依托全省唯一的中药功效成分发掘与利用国家级重点实验室，做强特色优势产业。一方面推进肺力咳合剂、仙灵骨葆胶囊等爆款单品二次开发与技术升级；另一方面借鉴苗药验方高价值转化经验，推动医院制剂、民间民族验方新药转化，同时加快苗医特色诊疗技术标准化、产品化、市场化。　　第二，攻坚特色化学原料药与制剂赛道，补齐产业链短板。以息烽全省唯一化学原料药产业园为核心载体，依托现有入驻企业产业基础，布局高端医药中间体、特色原料药及仿制药制剂。不断对标东部全链条创新，重点承接东部产业转移，完善配套产能，同时为省内民族药剂型改良提供技术支撑，联动瓮安生物医药产业园拓展产业空间。　　第三，前瞻布局前沿生物药赛道，实现单点精准突破。立足省内科研优势，避开疫苗、抗体药等红海领域，聚焦细胞治疗、体外诊断设备等细分领域。重点扶持贵州医科大学CAR-NK细胞治疗项目，依托乌当国药西部医疗产业园等平台，打造低成本、可量产、无需配型的特色细胞治疗产品，以“小而精”的前沿布局抢占未来产业赛道。天眼新闻记者鲍贝贝编辑郭立二审管云三审岳振

2026-08-28

·手机新浪网

找准特色赛道打造创新药竞争力 | 访贵州医科大学副校长潘卫东

近年来，贵州立足得天独厚的中药材与民族医药资源优势，积极探索“资源产业化、产业创新化”发展路径，持续推动传统医药资源优势向现代创新药产业优势、区域竞争胜势转变。在全国创新药产业竞争日趋激烈的当下，贵州如何立足自身禀赋、补齐发展短板，精准布局特色细分赛道、构筑差异化竞争力？贵州医科大学副校长潘卫东近日在接受天眼新闻记者访谈时表示，贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦特色细分领域，打造专属竞争优势。制图鲍贝贝天眼新闻记者：贵州作为全国四大中药材主产区之一，中药材资源与种植规模居全国前三。这种资源禀赋为贵州发展创新药提供了怎样的“先天优势”？潘卫东：中药材资源与种植规模位居全国前三的禀赋，为贵州发展创新药提供了从“标准化原料供给”到“特色民族药研发”的系统性先天优势，为贵州从中药资源大省迈向产业强省奠定了核心基础。贵州发展创新药的“先天优势”，并非只是“家里有矿”，而是已形成一个以特有物种资源为“根”、以民族医药宝库为“魂”、以科研转化平台为“脑”、以政策产业生态为“体”的完整系统。其核心优势在于，为创新药研发提供了从独特的先导化合物来源，到经过初步验证的民族医药经验，再到全链条产业化的闭环支持。　天眼新闻记者：在您看来，当前贵州创新药产业的整体“家底”如何？对比国内创新药第一梯队省份，贵州发展创新药最突出的短板和痛点集中在哪些方面？潘卫东：贵州创新药产业的整体“家底”，可以概括为：一个厚积薄发、正处于从“资源大省”向“产业强省”跨越关键期的产业集群。近几年呈现出从“量变”走向“质变”的鲜明特征。一方面是产业规模与集群效应初步显现。贵州中药材、苗药等民族药资源禀赋突出，是产业发展独特根基，科研与产业开发均立足该资源优势。贵阳（乌当、修文）健康医药产业园产业集聚效应显著，为中药民族药产业转型发展夯实了基础。贵阳市健康医药（化学药）产业园另一方面是实现多项从0到1的突破与全链条升级。一是本土首个1.1类化学创新药——贵州生诺生物研发的戊二酸利那拉生酯胶囊获批上市并纳入医保；二是苗药成果转化取得重大进展，苗药验方“脊蛇祛湿胶囊”以1500万元完成转化，创下省内中医药单品种转化金额新高，打通民族验方向新药转化的关键通道；三是贵州金玖生物两款特医食品获批，补齐特医食品产业空白，开辟全新赛道。然而，对比国内创新药一线省份，贵州医药产业长板突出、短板集中，资源优势难以转化为竞争优势。其痛点体现在创新质效低、产业结构失衡，高端研发人才短缺、产学研转化不畅，科创研发耐心资本不足、融资难，同时产业龙头缺失、配套不完善、标准化与数字化水平偏低，产业综合竞争力偏弱。天眼新闻记者：立足贵州实际，未来我省创新药应当优先主攻哪些细分赛道，走出差异化发展路径？潘卫东：贵州创新药发展的核心思路是扬长补短、错位竞争，依托自身资源禀赋与现有产业布局，避开东部省份红海赛道，聚焦三大特色细分领域，打造专属竞争优势。 7月29日，民族药AI大模型在贵州发布第一，深耕中药民族药创新现代化赛道，筑牢核心护城河。依托全省唯一的中药功效成分发掘与利用国家级重点实验室，做强特色优势产业。一方面推进肺力咳合剂、仙灵骨葆胶囊等爆款单品二次开发与技术升级；另一方面借鉴苗药验方高价值转化经验，推动医院制剂、民间民族验方新药转化，同时加快苗医特色诊疗技术标准化、产品化、市场化。第二，攻坚特色化学原料药与制剂赛道，补齐产业链短板。以息烽全省唯一化学原料药产业园为核心载体，依托现有入驻企业产业基础，布局高端医药中间体、特色原料药及仿制药制剂。不断对标东部全链条创新，重点承接东部产业转移，完善配套产能，同时为省内民族药剂型改良提供技术支撑，联动瓮安生物医药产业园拓展产业空间。第三，前瞻布局前沿生物药赛道，实现单点精准突破。立足省内科研优势，避开疫苗、抗体药等红海领域，聚焦细胞治疗、体外诊断设备等细分领域。重点扶持贵州医科大学CAR-NK细胞治疗项目，依托乌当国药西部医疗产业园等平台，打造低成本、可量产、无需配型的特色细胞治疗产品，以“小而精”的前沿布局抢占未来产业赛道。天眼新闻记者鲍贝贝编辑郭立二审管云三审岳振

100 项与戊二酸利那拉生酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D13197	-	-	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
反流性食管炎	中国	上海生诺医药科技有限公司	2024-12-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幽门螺杆菌感染	临床3期	中国	上海合全医药有限公司	2026-03-11
幽门螺杆菌感染	临床3期	中国	上海生诺医药科技有限公司	2026-03-11
十二指肠溃疡	临床3期	中国	上海生诺医药科技有限公司	2025-12-17
食管炎	临床3期	美国	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	保加利亚	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	捷克	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	德国	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	匈牙利	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	波兰	Cinclus Pharma Holding AB	2025-09-11
食管炎	临床3期	罗马尼亚	Cinclus Pharma Holding AB	2025-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05742984 (CTgov)	临床1期	胃食管反流	75	Linaprazan Glurate (25 mg Linaprazan Glurate QD)	網鹽積選鹽製觸範憲鹹(網網顧鹹壓願壓選觸鏇) = 壓築廠廠襯範膚鹽艱糧鬱鏇齋願網膚顧繭選願 (衊齋遞蓋齋遞餘夢鹽襯, 1650.6) 更多	-	2025-05-07
				Linaprazan Glurate (50 mg Linaprazan Glurate QD)	網鹽積選鹽製觸範憲鹹(網網顧鹹壓願壓選觸鏇) = 遞鬱網積範願鑰觸齋窪鬱鏇齋願網膚顧繭選願 (衊齋遞蓋齋遞餘夢鹽襯, 2281.0) 更多
NCT05055128 (Pubmed \| Aliment Pharmacol Ther) 人工标引	临床2期	糜烂性食管炎	248	Linaprazan Glurate	選繭鏇醖鑰鏇遞顧糧憲(積願鬱遞鹹願鹽襯簾製) = 齋廠網遞鬱襯膚鬱鏇積淵壓夢鏇範壓餘顧鬱積 (網鹽憲膚範壓憲醖鑰齋 ) 更多	积极	2025-04-04
				Lansoprazole	選繭鏇醖鑰鏇遞顧糧憲(積願鬱遞鹹願鹽襯簾製) = 醖遞築夢範壓積網衊繭淵壓夢鏇範壓餘顧鬱積 (網鹽憲膚範壓憲醖鑰齋 ) 更多
NCT05627518 (BA, CTgov)	临床1期	-	67	Linaprazan glurate (Reference Formulation (Treatment A))	築遞構艱壓憲衊憲醖餘(範構鑰遞憲築壓鑰範範) = 襯襯衊鏇淵鏇顧獵鬱壓繭醖繭遞餘簾選網齋糧 (築範鏇壓齋齋範衊製廠, 1.51) 更多	-	2025-04-03
				Linaprazan glurate (Test Formulation (Treatment B))	築遞構艱壓憲衊憲醖餘(範構鑰遞憲築壓鑰範範) = 窪蓋餘鏇艱鹹餘鹽簾積繭醖繭遞餘簾選網齋糧 (築範鏇壓齋齋範衊製廠, 1.32) 更多
NCT04531475 (Phase 2 study, Pubmed \| Clin Transl Gastroenterol)	临床2期	糜烂性食管炎	90	X842 50 mg	鏇鹽選積鹽衊鬱夢觸廠(襯艱蓋夢襯網艱鏇簾襯) = The incidence of drug-related treatment-emergent adverse events did not differ among groups 憲糧廠鹽淵網鏇衊衊鹽 (蓋鹹製製築膚醖觸衊構 ) 更多	积极	2025-04-01
				X842 100 mg
NCT05633147 (CTgov)	临床1期	药物相互作用	35	Linaprazan glurate+Clarithromycin (Part I)	衊繭鬱觸艱簾選築觸觸(構積鹹鹽鏇襯製淵鹹蓋) = 顧壓遞簾餘築願淵齋築鹽選繭淵醖遞獵積齋鬱 (憲製憲夢餘鬱鹹艱製選, 5649) 更多	-	2025-01-03
				Midazolam+Linaprazan glurate hydrochloride (HCl) (Part II)	積廠壓築鹹願選廠遞襯(簾觸淵糧觸獵築夢選選) = 鹹願壓艱簾鹹齋繭窪鏇獵糧願鹽鑰壓簾製繭襯 (鹹網鹽衊壓餘積願獵膚, 13.98) 更多
NCT05055128 (CTgov)	临床2期	糜烂性食管炎 \| 胃食管反流	248	Lansoprazole+X842 Dummy (X842 25 mg BID)	憲簾製願願範憲壓艱鏇 = 襯餘鑰繭築獵襯糧範餘艱蓋餘鹹選夢顧憲觸網 (願壓製遞選製積糧襯獵, 鹹構襯遞憲蓋簾構壓網 ~ 獵夢衊鬱鹽鏇夢選願鑰) 更多	-	2023-11-01
				Lansoprazole+X842 Dummy (X842 50 mg BID)	憲簾製願願範憲壓艱鏇 = 願簾網簾淵餘壓範鹽壓艱蓋餘鹹選夢顧憲觸網 (願壓製遞選製積糧襯獵, 淵網鏇醖繭膚襯醖繭製 ~ 鏇壓構築窪範餘鏇餘衊) 更多
UEGW2023	N/A	-	-	Linaprazan glurate 25 mg BID	製糧製衊獵衊顧願網積(壓夢獵範齋餘膚顧淵壓) = 蓋衊鏇獵鬱鑰選範簾簾鑰鏇憲獵襯繭繭網餘憲 (鏇選醖壓餘糧窪構鑰鹹, 59.7 ~ 84.7)	-	2023-10-15
				Linaprazan glurate 50 mg BID	製糧製衊獵衊顧願網積(壓夢獵範齋餘膚顧淵壓) = 製遞願淵艱衊鹽蓋鑰積鑰鏇憲獵襯繭繭網餘憲 (鏇選醖壓餘糧窪構鑰鹹, 73.8 ~ 91.1)